



## MannKind to Present at Upcoming Investor Conferences

05/13/25

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- **MannKind Corporation (Nasdaq: MNKD)**, a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced its participation at the upcoming investor conferences. MannKind's Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss will share updates during the following investor conferences, both being held in New York City:

### **RBC Capital Markets 2025 Global Annual Healthcare Conference**

Tuesday, May 20, 8:00 a.m. ET

### **Jefferies Global Healthcare Conference**

Thursday, June 5, 2:35 p.m. ET

Links to the live audio webcast of the sessions will be available on MannKind Corporation's website at: <https://investors.mannkindcorp.com/events-and-presentations>. Recorded versions will also be available on the website for approximately 90 days following the conference.

### **About MannKind**

MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.

We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication.

With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.

Please visit [mannkindcorp.com](http://mannkindcorp.com) to learn more, and follow us on [LinkedIn](#), [Facebook](#), [X](#) or [Instagram](#).

For MannKind: □  
Investor Relations  
Ana Kapor  
(818) 661-5000  
Email: [ir@mnkd.com](mailto:ir@mnkd.com)

Media Relations  
Christie Iacangelo  
(818) 292-3500  
Email: [media@mnkd.com](mailto:media@mnkd.com)



Source: MannKind